 |
11 Diseases |  |
39 Trials |
|
39 Trials |  |
2623 News |  |
| «12...27282930313233343536373839» |
- |||||||||| Tremfya (guselkumab) / J&J
New P3 trial: POLARIS: A Study to Compare the Efficacy of Guselkumab to Fumaric Acid Esters for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (clinicaltrials.gov) - Nov 1, 2016
P3b, N=114, Not yet recruiting, Sponsor: Janssen-Cilag G.m.b.H
- |||||||||| Tremfya (guselkumab) / J&J
New P3 trial: Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis (clinicaltrials.gov) - Sep 18, 2016
P3, N=75, Not yet recruiting, Sponsor: Janssen Research & Development, LLC
- || Tremfya (guselkumab) / J&J
Trial primary completion date: Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Active Psoriatic Arthritis (PsA) (clinicaltrials.gov) - Jul 19, 2016
P2a, N=149, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
Trial primary completion date: Jul 2017 --> May 2016
- |||| Tremfya (guselkumab) / J&J
Trial primary completion date: VOYAGE 2: A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis With Randomized Withdrawal and Retreatment (clinicaltrials.gov) - Jun 30, 2016
P3, N=998, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
Trial primary completion date: Jul 2017 --> May 2016 Trial primary completion date: May 2016 --> Oct 2015
- Tremfya (guselkumab) / J&J
Enrollment closed: Pharmacokinetic Study to Evaluate the Effect of a Single Dose of Guselkumab (CNTO 1959) on CYP 450 Enzyme Activities After Subcutaneous Administration in Participants With Psoriasis (clinicaltrials.gov) - Jun 29, 2016
P1, N=16, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
Trial primary completion date: May 2016 --> Oct 2015 Recruiting --> Active, not recruiting
- ||||||| Stelara (ustekinumab) / J&J, Tremfya (guselkumab) / J&J
Trial completion, Trial primary completion date: NAVIGATE: A Study of Guselkumab in Participants With Moderate to Severe Plaque-type Psoriasis and an Inadequate Response to Ustekinumab (clinicaltrials.gov) - Jun 24, 2016
P3, N=876, Completed, Sponsor: Janssen Research & Development, LLC
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | Trial primary completion date: May 2016 --> Dec 2015
- ||| Tremfya (guselkumab) / J&J
Enrollment closed: Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Active Psoriatic Arthritis (PsA) (clinicaltrials.gov) - Jun 23, 2016
P2a, N=149, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
Active, not recruiting --> Completed | Trial primary completion date: May 2016 --> Dec 2015 Recruiting --> Active, not recruiting
- |||| Tremfya (guselkumab) / J&J
Trial primary completion date: VOYAGE 1: A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis (clinicaltrials.gov) - Jun 18, 2016
P3, N=841, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
Recruiting --> Active, not recruiting Trial primary completion date: May 2015 --> Sep 2015
- Tremfya (guselkumab) / J&J
Trial primary completion date: Pharmacokinetic Study to Evaluate the Effect of a Single Dose of Guselkumab (CNTO 1959) on CYP 450 Enzyme Activities After Subcutaneous Administration in Participants With Psoriasis (clinicaltrials.gov) - Jun 9, 2016
P1, N=18, Recruiting, Sponsor: Janssen Research & Development, LLC
Trial primary completion date: May 2015 --> Sep 2015 Trial primary completion date: May 2016 --> Sep 2016
- |||| Tremfya (guselkumab) / J&J
Trial primary completion date: VOYAGE 1: A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis (clinicaltrials.gov) - Jun 5, 2016
P3, N=841, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
Trial primary completion date: May 2016 --> Sep 2016 Trial primary completion date: Apr 2016 --> May 2015
- | Tremfya (guselkumab) / J&J
Phase classification: Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Active Psoriatic Arthritis (PsA) (clinicaltrials.gov) - Jun 2, 2016
P2a, N=150, Recruiting, Sponsor: Janssen Research & Development, LLC
Trial primary completion date: Apr 2016 --> May 2015 Phase classification: P2 --> P2a
- Tremfya (guselkumab) / J&J
Trial primary completion date: Pharmacokinetic Study to Evaluate the Effect of a Single Dose of Guselkumab (CNTO 1959) on CYP 450 Enzyme Activities After Subcutaneous Administration in Participants With Psoriasis (clinicaltrials.gov) - May 16, 2016
P1, N=18, Recruiting, Sponsor: Janssen Research & Development, LLC
Phase classification: P2 --> P2a Trial primary completion date: Feb 2016 --> May 2016
- |||| Stelara (ustekinumab) / J&J, Tremfya (guselkumab) / J&J
Trial primary completion date: NAVIGATE: A Study of Guselkumab in Participants With Moderate to Severe Plaque-type Psoriasis and an Inadequate Response to Ustekinumab (clinicaltrials.gov) - Apr 22, 2016
P3, N=876, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
Trial primary completion date: Feb 2016 --> May 2016 Trial primary completion date: Aug 2016 --> May 2016
- Tremfya (guselkumab) / J&J
Trial completion: A Study to Characterize the Elimination of Guselkumab Glycoform Variants in Healthy Participants (clinicaltrials.gov) - Apr 12, 2016
P1, N=8, Completed, Sponsor: Janssen Research & Development, LLC
Trial primary completion date: Aug 2016 --> May 2016 Recruiting --> Completed
- ||||| Tremfya (guselkumab) / J&J
Enrollment closed: VOYAGE 2: A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis With Randomized Withdrawal and Retreatment (clinicaltrials.gov) - Feb 17, 2016
P3, N=999, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
Recruiting --> Completed Recruiting --> Active, not recruiting
- | Tremfya (guselkumab) / J&J
Enrollment open: An Efficacy and Safety Study of CNTO1959 (Guselkumab) in the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis (clinicaltrials.gov) - Jan 26, 2016
P3, N=20, Recruiting, Sponsor: Janssen Pharmaceutical K.K.
Recruiting --> Active, not recruiting Active, not recruiting --> Recruiting
- |||| Tremfya (guselkumab) / J&J
Trial primary completion date: VOYAGE 1: A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis (clinicaltrials.gov) - Jan 17, 2016
P3, N=833, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
Active, not recruiting --> Recruiting Trial primary completion date: Oct 2015 --> Apr 2016
- |||||||||| Tremfya (guselkumab) / J&J
New P3 trial: An Efficacy and Safety of Guselkumab in Participants With Palmoplantar Pustulosis (clinicaltrials.gov) - Dec 29, 2015
P3, N=225, Recruiting, Sponsor: Janssen Pharmaceutical K.K.
- Tremfya (guselkumab) / J&J
Enrollment open: A Study to Characterize the Elimination of Guselkumab Glycoform Variants in Healthy Participants (clinicaltrials.gov) - Nov 3, 2015
P1, N=8, Recruiting, Sponsor: Janssen Research & Development, LLC
Trial primary completion date: Oct 2015 --> Apr 2016 Not yet recruiting --> Recruiting
- |||| Tremfya (guselkumab) / J&J
Trial primary completion date: VOYAGE 2: A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis With Randomized Withdrawal and Retreatment (clinicaltrials.gov) - Nov 1, 2015
P3, N=1000, Recruiting, Sponsor: Janssen Research & Development, LLC
Not yet recruiting --> Recruiting Trial primary completion date: Sep 2015 --> May 2016
- | Tremfya (guselkumab) / J&J
Enrollment closed: An Efficacy and Safety Study of CNTO1959 (Guselkumab) in the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis (clinicaltrials.gov) - Oct 30, 2015
P3, N=21, Active, not recruiting, Sponsor: Janssen Pharmaceutical K.K.
Trial primary completion date: Sep 2015 --> May 2016 Recruiting --> Active, not recruiting
- Tremfya (guselkumab) / J&J
Enrollment open: Pharmacokinetic Study to Evaluate the Effect of a Single Dose of Guselkumab (CNTO 1959) on CYP 450 Enzyme Activities After Subcutaneous Administration in Participants With Psoriasis (clinicaltrials.gov) - Oct 27, 2015
P1, N=18, Recruiting, Sponsor: Janssen Research & Development, LLC
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- Tremfya (guselkumab) / J&J
New P1 trial: A Study to Characterize the Elimination of Guselkumab Glycoform Variants in Healthy Participants (clinicaltrials.gov) - Oct 7, 2015
P1, N=8, Not yet recruiting, Sponsor: Janssen Research & Development, LLC
- ||||| Stelara (ustekinumab) / J&J, Tremfya (guselkumab) / J&J
Enrollment closed: NAVIGATE: A Study of Guselkumab in Participants With Moderate to Severe Plaque-type Psoriasis and an Inadequate Response to Ustekinumab (clinicaltrials.gov) - Sep 28, 2015
P3, N=876, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- Tremfya (guselkumab) / J&J
Trial initiation date: Pharmacokinetic Study to Evaluate the Effect of a Single Dose of Guselkumab (CNTO 1959) on CYP 450 Enzyme Activities After Subcutaneous Administration in Participants With Psoriasis (clinicaltrials.gov) - Sep 8, 2015
P1, N=18, Not yet recruiting, Sponsor: Janssen Research & Development, LLC
Recruiting --> Active, not recruiting Initiation date: Mar 2015 --> Jun 2015
- ||||| Tremfya (guselkumab) / J&J
Enrollment change: An Efficacy and Safety of CNTO 1959 (Guselkumab) in Participants With Moderate to Severe Plaque-type Psoriasis (clinicaltrials.gov) - Aug 14, 2015
P3, N=226, Recruiting, Sponsor: Janssen Pharmaceutical K.K.
Initiation date: Mar 2015 --> Jun 2015 N=180 --> 226
- | Tremfya (guselkumab) / J&J
Enrollment closed: VOYAGE 1: A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis (clinicaltrials.gov) - Jul 6, 2015
P3, N=833, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
N=180 --> 226 Recruiting --> Active, not recruiting
- | Tremfya (guselkumab) / J&J
Enrollment open: An Efficacy and Safety Study of CNTO1959 (Guselkumab) in the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis (clinicaltrials.gov) - Apr 6, 2015
P3, N=20, Recruiting, Sponsor: Janssen Pharmaceutical K.K.
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- |||| Tremfya (guselkumab) / J&J
Enrollment open: Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Active Psoriatic Arthritis (PsA) (clinicaltrials.gov) - Apr 6, 2015
P2, N=150, Recruiting, Sponsor: Janssen Research & Development, LLC
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Tremfya (guselkumab) / J&J
New P1 trial: Pharmacokinetic Study to Evaluate the Effect of a Single Dose of Guselkumab (CNTO 1959) on CYP 450 Enzyme Activities After Subcutaneous Administration in Participants With Psoriasis (clinicaltrials.gov) - Mar 26, 2015
P1, N=18, Not yet recruiting, Sponsor: Janssen Research & Development, LLC
- |||| Tremfya (guselkumab) / J&J
Trial completion: X-PLORE: A Study to Evaluate CNTO 1959 in the Treatment of Patients With Moderate to Severe Plaque-type Psoriasis (clinicaltrials.gov) - Feb 9, 2015
P2, N=293, Completed, Sponsor: Janssen Inc.
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- |||||| Tremfya (guselkumab) / J&J
Enrollment open: An Efficacy and Safety of CNTO 1959 (Guselkumab) in Participants With Moderate to Severe Plaque-type Psoriasis (clinicaltrials.gov) - Feb 5, 2015
P3, N=180, Recruiting, Sponsor: Janssen Pharmaceutical K.K.
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- ||| Tremfya (guselkumab) / J&J
New P3 trial: An Efficacy and Safety Study of CNTO1959 (Guselkumab) in the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis (clinicaltrials.gov) - Jan 22, 2015
P3, N=20, Not yet recruiting, Sponsor: Janssen Pharmaceutical K.K.
- || Tremfya (guselkumab) / J&J
Trial primary completion date: Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Active Psoriatic Arthritis (PsA) (clinicaltrials.gov) - Jan 18, 2015
P2, N=150, Not yet recruiting, Sponsor: Janssen Research & Development, LLC
Not yet recruiting --> Recruiting Trial primary completion date: Dec 2016 --> Jul 2017
- |||||||||| Tremfya (guselkumab) / J&J
New P3 trial: An Efficacy and Safety of CNTO 1959 (Guselkumab) in Participants With Moderate to Severe Plaque-type Psoriasis (clinicaltrials.gov) - Dec 24, 2014
P3, N=180, Not yet recruiting, Sponsor: Janssen Pharmaceutical K.K.
- ||||| Tremfya (guselkumab) / J&J
New P2 trial: Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Active Psoriatic Arthritis (PsA) (clinicaltrials.gov) - Dec 19, 2014
P2, N=150, Not yet recruiting, Sponsor: Janssen Research & Development, LLC
- |||||| Tremfya (guselkumab) / J&J
Enrollment open: VOYAGE 1: A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis (clinicaltrials.gov) - Dec 17, 2014
P3, N=750, Recruiting, Sponsor: Janssen Research & Development, LLC
Trial primary completion date: Dec 2016 --> Jul 2017 Not yet recruiting --> Recruiting
- |||||| Tremfya (guselkumab) / J&J
Enrollment open: VOYAGE 2: A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis With Randomized Withdrawal and Retreatment (clinicaltrials.gov) - Nov 19, 2014
P3, N=1000, Recruiting, Sponsor: Janssen Research & Development, LLC
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Tremfya (guselkumab) / J&J
Trial completion: A Study of the Efficacy, Safety and Tolerability of CNTO 1959, a Human Anti-IL 23 Monoclonal Antibody in Participants With Palmoplantar Pustulosis (clinicaltrials.gov) - Nov 19, 2014
P2, N=49, Completed, Sponsor: Janssen Pharmaceutical K.K.
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- |||||| Stelara (ustekinumab) / J&J, Tremfya (guselkumab) / J&J
Enrollment open: NAVIGATE: A Study of Guselkumab in Participants With Moderate to Severe Plaque-type Psoriasis and an Inadequate Response to Ustekinumab (clinicaltrials.gov) - Sep 19, 2014
P3, N=800, Recruiting, Sponsor: Janssen Research & Development, LLC
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- |||||||||| Tremfya (guselkumab) / J&J
New P3 trial: VOYAGE 2: A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis With Randomized Withdrawal and Retreatment (clinicaltrials.gov) - Aug 4, 2014
P3, N=1000, Not yet recruiting, Sponsor: Janssen Research & Development, LLC
- |||||||||| Tremfya (guselkumab) / J&J
New P3 trial: VOYAGE 1: A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis (clinicaltrials.gov) - Aug 4, 2014
P3, N=750, Not yet recruiting, Sponsor: Janssen Research & Development, LLC
- |||||||||| Stelara (ustekinumab) / J&J, Tremfya (guselkumab) / J&J
New P3 trial: NAVIGATE: A Study of Guselkumab in Participants With Moderate to Severe Plaque-type Psoriasis and an Inadequate Response to Ustekinumab (clinicaltrials.gov) - Jul 30, 2014
P3, N=800, Not yet recruiting, Sponsor: Janssen Research & Development, LLC
- || Stelara (ustekinumab) / J&J, Tremfya (guselkumab) / J&J
Trial completion date: A Study of the Effectiveness and Safety of Ustekinumab (STELARA) and CNTO 1959 Administered Under the Skin of Patients With Active Rheumatoid Arthritis, Despite Existing Methotrexate Therapy (clinicaltrials.gov) - May 14, 2014
P2, N=274, Completed, Sponsor: Janssen Research & Development, LLC
Not yet recruiting --> Recruiting Trial completion date: Jun 2014 --> May 2014
- |||| Stelara (ustekinumab) / J&J, Tremfya (guselkumab) / J&J
Trial completion: A Study of the Effectiveness and Safety of Ustekinumab (STELARA) and CNTO 1959 Administered Under the Skin of Patients With Active Rheumatoid Arthritis, Despite Existing Methotrexate Therapy (clinicaltrials.gov) - May 14, 2014
P2, N=274, Completed, Sponsor: Janssen Research & Development, LLC
Trial completion date: Jun 2014 --> May 2014 Active, not recruiting --> Completed
- | Tremfya (guselkumab) / J&J
Enrollment change: A Study of the Efficacy, Safety and Tolerability of CNTO 1959, a Human Anti-IL 23 Monoclonal Antibody in Participants With Palmoplantar Pustulosis (clinicaltrials.gov) - May 11, 2014
P2, N=49, Active, not recruiting, Sponsor: Janssen Pharmaceutical K.K.
Active, not recruiting --> Completed N=63 --> 49
- | Tremfya (guselkumab) / J&J
Enrollment closed: A Study of the Efficacy, Safety and Tolerability of CNTO 1959, a Human Anti-IL 23 Monoclonal Antibody in Participants With Palmoplantar Pustulosis (clinicaltrials.gov) - May 11, 2014
P2, N=49, Active, not recruiting, Sponsor: Janssen Pharmaceutical K.K.
N=63 --> 49 Recruiting --> Active, not recruiting
- ||| Tremfya (guselkumab) / J&J
Trial completion: A Study to Assess the Pharmacokinetic Comparability of Guselkumab (CNTO1959) When Delivered by 2 Different Devices and as 2 Formulations in Healthy Participants (clinicaltrials.gov) - Nov 17, 2013
P1, N=141, Completed, Sponsor: Janssen Research & Development, LLC
Recruiting --> Active, not recruiting Recruiting --> Completed
- Tremfya (guselkumab) / J&J
Enrollment change: A Study of the Safety, Tolerability, Pharmacokinetics (What the Body Does to the Drug), and Pharmacodynamics (What the Drug Does to the Body) of CNTO 1959 Following a Single Subcutaneous (Under the Skin) Administration in Japanese Participants With Moderate to Severe Plaque Psoriasis (clinicaltrials.gov) - Jun 23, 2013
P1, N=24, Completed, Sponsor: Janssen Pharmaceutical K.K.
Recruiting --> Completed N=32 --> 24
- |||| Tremfya (guselkumab) / J&J
Enrollment open: A Study of the Efficacy, Safety and Tolerability of CNTO 1959, a Human Anti-IL 23 Monoclonal Antibody in Participants With Palmoplantar Pustulosis (clinicaltrials.gov) - Jun 23, 2013
P2, N=63, Recruiting, Sponsor: Janssen Pharmaceutical K.K.
N=32 --> 24 Not yet recruiting --> Recruiting